In conclusion, with regard to the nature of their cooperation and in the light of the conditions as set out in the Leniency Notice, the adressees of this Decision should be granted the following reduction of their respective fines:
–
to Rhône-Poulenc Biochimie SA/Aventis Pharma SA, a reduction of 40 %
–
to Merck KgaA a reduction of 100 %.
3.3.8. The final amounts of the fines imposed in the present proceedings